Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) EBT: 2020-2025

Historic EBT for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$56.9 million.

  • 4D Molecular Therapeutics' EBT fell 29.68% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.1 million, marking a year-over-year decrease of 45.83%. This contributed to the annual value of -$160.8 million for FY2024, which is 59.74% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported EBT of -$56.9 million as of Q3 2025, which was down 4.14% from -$54.6 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' EBT's 5-year high stood at -$7.6 million during Q2 2021, with a 5-year trough of -$56.9 million in Q3 2025.
  • In the last 3 years, 4D Molecular Therapeutics' EBT had a median value of -$34.9 million in 2024 and averaged -$38.3 million.
  • In the last 5 years, 4D Molecular Therapeutics' EBT soared by 60.71% in 2023 and then crashed by 334.17% in 2024.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' EBT stood at -$25.1 million in 2021, then fell by 9.20% to -$27.4 million in 2022, then fell by 17.86% to -$32.3 million in 2023, then crashed by 53.85% to -$49.6 million in 2024, then declined by 29.68% to -$56.9 million in 2025.
  • Its EBT stands at -$56.9 million for Q3 2025, versus -$54.6 million for Q2 2025 and -$48.0 million for Q1 2025.